John Miles, MD
Endocrinology, Diabetes & Metabolism · Kansas City, KSNPI 1164494233
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,503 of the $12,807 with a category attached, or 82.0%. 19 manufacturers reported payments, led by Novo Nordisk at 40.0% of the total. Reporting peaked in 2019 at $6,742 and has fallen 96.8% since, to $217 in 2025.
Across 85 payments — averaging $150.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$5K
- Sanofi-aventis U.S. LLC$3K
- Roche Diabetes Care GmbH$2K
- Baxter Healthcare$2K
- Lilly USA, LLC$284
- Xeris Pharmaceuticals, Inc.$211
- plus $463 from 13 others
What the payments were for
- Consulting fees$10,50382%
- Food & beverage$2,27218%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $5,124 |
| Sanofi-aventis U.S. LLC | 11 | $3,342 |
| Roche Diabetes Care GmbH | 1 | $1,875 |
| Baxter Healthcare | 3 | $1,508 |
| Lilly USA, LLC | 10 | $284 |
| Xeris Pharmaceuticals, Inc. | 18 | $211 |
| Fresenius Kabi USA, LLC | 1 | $109 |
| Alcresta Therapeutics, Inc. | 1 | $90 |
| Amarin Pharma, Inc. | 1 | $59 |
| Esperion Therapeutics, Inc. | 1 | $52 |
| AstraZeneca | 2 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Merck | 1 | $17 |
| Medtronic | 1 | $15 |
| BETA Bionics, Inc. | 1 | $15 |
| Abbott | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,807 in reported general payments places this provider in the 85th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 388 | $497,684 |
| OzempicSemaglutide | 250 | $379,756 |
| JardianceEmpagliflozin | 246 | $267,359 |
| TrulicityDulaglutide | 69 | $104,172 |
| FarxigaDapagliflozin Propanediol | 34 | $30,612 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $21,074 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $18,620 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $15,188 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $12,854 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $8,165 |
| Novolog FlexpenInsulin Aspart | 32 | $7,829 |
| XyostedTestosterone Enanthate | 11 | $6,911 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $6,648 |
| Metformin Hcl | 163 | $5,010 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 38 | $4,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $284 | $601,857457 claims |
| Novo NordiskOzempic, Novolog | $5,124 | $383,636261 claims |
| Boehringer IngelheimJardiance | $18 | $267,359246 claims |
| AstraZenecaFarxiga | $25 | $30,61234 claims |
| Antares Pharma, Inc.Xyosted | $12 | $6,91111 claims |
| Sanofi-aventis U.S. LLCLantus | $3,342 | $1,10315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $38856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Kansas City
- Charlotte BurnsKansas City$3K
- Rudruidee KarnchanasornKansas City$2K
- Kristine GrdinovacKansas City$1K
- Aiman ZafarKansas City$492
- Tinni MishraKansas City$199
- Daniel TildenKansas City$128
- Prathyusha PagadalaKansas City$89
- Joseph KynerKansas City$74
- Leland GravesKansas City$57
- Abeer AnabtawiKansas City$56
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.